Head Genetics Fraud Allegations Cost Investors Millions

Recent lawsuit filings have brought to light the truth about Head Genetics and its claims, particularly related to the Head Genetics concussion test. As the Head Genetics lawsuit continues to unfold, many are drawing comparisons to Head Genetics Inc and its controversial practices reminiscent of the Theranos scandal.

Head Genetics Inc concussion test kit under scrutiny for lack of testing and FDA approval claims

Head Genetics - What Investors Need to Know Before Getting Involved

Head Genetics Inc. is a Nashville-based biotech startup that claims to be developing a saliva-based concussion assessment device, known as the Head Genetics concussion test. The company promotes a narrative that this project “started” in 2013, aiming to capture a share of the multibillion-dollar traumatic brain injury diagnostic market.

However, public records and opposition research reveal a very different story about Head Genetics. Incorporated in 2022, Head Genetics Inc. has raised no external funding, lacks FDA approvals and active clinical trials, and is currently entangled in a Head Genetics lawsuit initiated by investors who allege they were misled.

This site exists to assist potential investors, partners, and counterparties in understanding the legal, regulatory, financial, and credibility risks associated with Head Genetics before they commit their capital or reputation, drawing parallels to the Theranos situation.

About Head Genetics

Head Genetics, also known as Head Genetics Inc., positions itself as a biotech company that focuses on a non-invasive, over-the-counter saliva test designed to assess concussions. Their marketing emphasizes the Head Genetics concussion test as "easy to use," "inexpensive & fast," utilizing "BPA-free, FDA-approved, premium materials." Despite claims that the project began in 2013, Head Genetics was incorporated in 2022 and is located in Nashville, Tennessee. This saliva-based concussion assessment device is marketed as a consumer-friendly diagnostic tool. However, it is important to note that no external funding rounds for Head Genetics have been identified in major startup databases, and no FDA approvals or clinical trials have been registered on ClinicalTrials.gov under the company's name.

The market positioning suggests a potential share in the traumatic brain injury diagnostic market, which is estimated to reach between $1.75B and $3B in the coming years. For a medical device company like Head Genetics, which operates in a highly regulated and capital-intensive space, the absence of funding, trials, and approvals is not a trivial concern. Additionally, the Head Genetics lawsuit and comparisons to Theranos have raised questions about its credibility. We offer a wide range of services, including consultancy, project management, and training, working closely with our clients to provide tailored solutions that help them achieve their objectives. Our mission is to support our clients' success in their respective industries.

Why the focus on Head Genetics?

This website serves as a due diligence companion for anyone evaluating Head Genetics Inc. as an investment, grant recipient, strategic partner, or charitable vehicle.

Information here is drawn from:

Public court records in Dallas County, Texas (Case No. DC-24-21484) and Cook County, Illinois (Case No. 2025-L-010360)

Regulatory and clinical trial databases

Company website claims and marketing materials

Independent opposition research compiled from open sources

Investors Solidaris Capital LLC and Cirrus Investments LLC have sued Head Genetics Inc., Carita Investments L.L.C., and Mark Bianchi over what they describe as a failed 'Tech2head Recovery' charitable deduction securities offering. Their filings allege misrepresentation of the company’s timeline, regulatory status, and the founders’ track records, especially regarding the Head Genetics concussion test.

The goal of this site is not to tell you what to do with your money. Instead, it aims to ensure that anyone searching for 'Head Genetics' or 'Head Genetics Lawsuit' can easily find the facts and the core questions that remain unanswered, including those related to Head Genetics and its controversies reminiscent of the Theranos case.

Key Red Flags Around Head Genetics Inc.

Based on court filings, regulatory checks, and published opposition research, several issues should concern any potential investor in Head Genetics Inc:

- Active securities litigation involving Solidaris Capital and Cirrus Investments, alleging fraud in connection with charitable deduction securities tied to Head Genetics’ technology.

- Zero external funding raised, despite operating in a sector where medical device development typically requires tens of millions of dollars for trials and approval processes.

- No FDA approvals or clearances for the Head Genetics concussion test, and no listed clinical trials, despite claims of a decade-long project timeline.

- Timeline discrepancy: Head Genetics claims the project began in 2013, yet the corporation was formed in 2022, creating a nine-year gap that raises questions about intellectual property and development continuity.

- Leadership experience misalignment: the founding team’s background is heavily focused on branding and commercial roles, with limited publicly verifiable experience in medical device regulation or FDA pathways.

- Competitive disadvantage in a crowded concussion diagnostics market where competitors already hold FDA-cleared tests, patents, and academic backing.

Industry experts quoted in the research describe this combination as an unusual cluster of risk factors for any legitimate early-stage medical device company, raising concerns similar to those surrounding the Head Genetics lawsuit and comparisons to Theranos.

Head Genetics Lawsuits

Head Genetics Inc. and related entities are currently embroiled in a multi-jurisdictional legal battle concerning the 'Tech2head Recovery' securities offering, which has drawn significant attention due to its implications for investors in the Head Genetics concussion test.

In Texas, Solidaris Capital LLC and Cirrus Investments LLC have filed a lawsuit against Head Genetics Inc., Carita Investments L.L.C., and Mark Bianchi.

- Court: Dallas County, Texas

- Case No.: DC-24-21484

- Filed: December 10, 2024

Additionally, there are ongoing proceedings in Illinois regarding the same investment structure.

- Court: Cook County, Illinois

- Case No.: 2025-L-010360

- Filed: August 18, 2025

The lawsuits characterize the investment as a charitable deduction securities offering and allege that investors were misled about the project's age, FDA status, and the founders' claimed prior exits. These claims have raised parallels to the Head Genetics lawsuit against Theranos, as discovery efforts have expanded to include third parties such as Exemplar Capital LLC, Valiant Strategies Group LLC, Valiant Investment Holdings LLC, and Morgan Stanley & Co. LLP.

Before You Invest in Head Genetics

If you are evaluating Head Genetics Inc. as an investment or partner, the minimum steps should include:

Confirm any FDA claims regarding the Head Genetics concussion test directly through FDA.gov.

Check ClinicalTrials.gov for any studies related to Head Genetics.

Verify the company formation dates against the claimed project timelines connected to Head Genetics.

Independently verify any claimed exits or revenue figures for prior companies associated with the founders, especially in light of the recent Head Genetics lawsuit.

Review court records in Texas and Illinois for the status and details of the lawsuits involving Head Genetics.

Read recent news stories about Head Genetics Inc. legal issues.

Consult an independent medical device regulatory expert, rather than relying solely on the company’s marketing materials, especially considering comparisons to Head Genetics and Theranos.